CL2022000102A1 - Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos. - Google Patents

Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.

Info

Publication number
CL2022000102A1
CL2022000102A1 CL2022000102A CL2022000102A CL2022000102A1 CL 2022000102 A1 CL2022000102 A1 CL 2022000102A1 CL 2022000102 A CL2022000102 A CL 2022000102A CL 2022000102 A CL2022000102 A CL 2022000102A CL 2022000102 A1 CL2022000102 A1 CL 2022000102A1
Authority
CL
Chile
Prior art keywords
pyridazin
pyrido
dihydro
derivatives
pharmaceutical compositions
Prior art date
Application number
CL2022000102A
Other languages
English (en)
Inventor
Attila Paczal
András Kotschy
James Edward Paul Davidson
Maïa Chanrion
Ana Leticia Maragno
James Brooke Murray
Simon Bedford
Frédéric Colland
Mark Philip Dodsworth
András Herner
Mátyás Pál Timári
Paul Webb
Jérôme-Benoit Starck
Emma Sanders
Tibor Novak
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CL2022000102A1 publication Critical patent/CL2022000102A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de fórmula (I): en donde Het, Het1, Het2, A4, A5, Z1, R1, R2 y R3 son como se definen en la descripción. Medicamentos.
CL2022000102A 2019-07-29 2022-01-13 Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos. CL2022000102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19188749 2019-07-29

Publications (1)

Publication Number Publication Date
CL2022000102A1 true CL2022000102A1 (es) 2022-11-04

Family

ID=67514283

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000102A CL2022000102A1 (es) 2019-07-29 2022-01-13 Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.

Country Status (38)

Country Link
US (1) US12570648B2 (es)
EP (1) EP4003989B1 (es)
JP (1) JP7805283B2 (es)
KR (1) KR102987787B1 (es)
CN (1) CN114450284B (es)
AR (1) AR119494A1 (es)
AU (1) AU2020319652B2 (es)
BR (1) BR112022001373A2 (es)
CL (1) CL2022000102A1 (es)
CO (1) CO2022000612A2 (es)
CR (1) CR20220016A (es)
DK (1) DK4003989T3 (es)
DO (1) DOP2022000019A (es)
ES (1) ES2975087T3 (es)
FI (1) FI4003989T3 (es)
GE (2) GEP20237581B (es)
HR (1) HRP20240392T1 (es)
HU (1) HUE065742T2 (es)
IL (1) IL289933B2 (es)
JO (1) JOP20220010A1 (es)
LT (1) LT4003989T (es)
MA (1) MA56649B1 (es)
MD (1) MD4003989T2 (es)
MX (1) MX2022001191A (es)
MY (1) MY207131A (es)
PE (1) PE20220705A1 (es)
PH (1) PH12022550119A1 (es)
PL (1) PL4003989T3 (es)
PT (1) PT4003989T (es)
PY (1) PY2039847A (es)
RS (1) RS65248B1 (es)
SA (1) SA522431522B1 (es)
SI (1) SI4003989T1 (es)
TW (1) TWI751629B (es)
UA (1) UA130017C2 (es)
UY (1) UY38810A (es)
WO (1) WO2021018858A1 (es)
ZA (1) ZA202200828B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
CN116761635A (zh) * 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
JP2024505562A (ja) * 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
CN114181039A (zh) * 2021-12-23 2022-03-15 凯美克(上海)医药科技有限公司 一种4,4-二苯基-3-丁烯-1-醇的合成方法
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
JP2026508178A (ja) 2023-02-14 2026-03-10 シェンチェン ジョンジー バイオロジカル テクノロジー カンパニー, リミテッド Nlrp3を阻害する化合物及びその製造方法と応用
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200730527A (en) 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
KR101685718B1 (ko) * 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
CN103987711B (zh) * 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
TW201414737A (zh) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3229844B1 (en) 2014-12-09 2020-03-04 AbbVie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
JP2018502839A (ja) 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
RU2017123942A (ru) 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
WO2017097870A1 (de) * 2015-12-11 2017-06-15 Bayer Cropscience Aktiengesellschaft Substituierte malonsäureamide als insektizide
MX2018015284A (es) 2016-06-08 2019-09-18 Abbvie Inc Conjugados de anticuerpo anti-egfr y fármaco.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
KR102987787B1 (ko) 2026-07-07
PT4003989T (pt) 2024-01-30
AR119494A1 (es) 2021-12-22
PE20220705A1 (es) 2022-05-04
GEP20237581B (en) 2023-12-25
AU2020319652A1 (en) 2022-02-10
JOP20220010A1 (ar) 2023-01-30
PL4003989T3 (pl) 2024-04-29
CN114450284B (zh) 2024-05-07
SI4003989T1 (sl) 2024-04-30
HUE065742T2 (hu) 2024-06-28
JP2022542595A (ja) 2022-10-05
IL289933A (en) 2022-03-01
AU2020319652B2 (en) 2026-05-14
TWI751629B (zh) 2022-01-01
DK4003989T3 (da) 2024-03-25
TW202118764A (zh) 2021-05-16
BR112022001373A2 (pt) 2022-06-07
FI4003989T3 (fi) 2024-03-21
KR20220041132A (ko) 2022-03-31
DOP2022000019A (es) 2022-05-15
CN114450284A (zh) 2022-05-06
US20220363677A1 (en) 2022-11-17
IL289933B1 (en) 2024-11-01
IL289933B2 (en) 2025-03-01
UA130017C2 (uk) 2025-10-15
SA522431522B1 (ar) 2024-04-30
MY207131A (en) 2025-01-31
MX2022001191A (es) 2022-02-22
PY2039847A (es) 2021-05-03
US12570648B2 (en) 2026-03-10
ZA202200828B (en) 2024-08-28
RS65248B1 (sr) 2024-03-29
GEAP202315865A (en) 2023-08-25
JP7805283B2 (ja) 2026-01-23
WO2021018858A1 (en) 2021-02-04
ES2975087T3 (es) 2024-07-03
LT4003989T (lt) 2024-02-12
CO2022000612A2 (es) 2022-01-28
MA56649B1 (fr) 2024-02-29
CR20220016A (es) 2022-03-02
MD4003989T2 (ro) 2024-06-30
PH12022550119A1 (en) 2022-11-21
CA3148506A1 (en) 2021-02-04
HRP20240392T1 (hr) 2024-06-07
UY38810A (es) 2021-02-26
EP4003989B1 (en) 2023-12-27
EP4003989A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
DOP2022000019A (es) DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
DOP2022000015A (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
CL2019000169A1 (es) Derivados de piperidina.
MX374443B (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
MX2018015216A (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
BR112017000169A2 (pt) picolinamidas macrocíclicas como fungicidas
IN2015DN00538A (es)
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
FR3041639B1 (fr) NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
PY2201650A (es) Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
UY29486A1 (es) Compuestos utiles en terapia
CL2020001817A1 (es) Moduladores del receptor c5a
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CO2018011231A2 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad por los receptores canabinoides tipo-2
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
BR112015024113A2 (pt) derivados de uréia e seu uso como inibidores da proteína de ligação de ácido graxo (fabp)
PY1953761A (es) Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112022020239A2 (pt) Derivados de quinolina di-hidro-(tiazina)oxazina microbiocidas
BR112022020318A2 (pt) Derivados de quinolina di-hidro-(tiazina)oxazina microbiocidas
TR201818990A2 (tr) Sefdi̇ni̇r i̇çeren tablet formülasyonu
FR3022245B1 (fr) Derives de 3,5-dihydro-2h-pyrazolo[4,3-c]pyridin-3-one et leur utilisation